{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:27:22Z","timestamp":1791260842506,"version":"4.1.0"},"reference-count":75,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2015,6,10]],"date-time":"2015-06-10T00:00:00Z","timestamp":1433894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Gastro and Hepatol"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Advanced cholangiocarcinoma (<jats:styled-content style=\"fixed-case\">CCA<\/jats:styled-content>) is a highly lethal disease with limited therapeutic options beyond cytotoxic chemotherapy. Molecular profiling of <jats:styled-content style=\"fixed-case\">CCA<\/jats:styled-content> has provided insights into the pathogenesis of this disease and identified potential therapeutic targets. The fibroblast growth factor receptor (<jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>) axis is important for maintaining tissue homeostasis. Aberrations in <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> activity have been implicated in the development and progression of <jats:styled-content style=\"fixed-case\">CCA<\/jats:styled-content> and other malignancies, which has generated significant interest in exploring <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>'s therapeutic potential. <jats:styled-content style=\"fixed-case\">FGFR2<\/jats:styled-content> fusion events are present in up to 17% of intrahepatic <jats:styled-content style=\"fixed-case\">CCAs<\/jats:styled-content> and appear to predict sensitivity to <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> inhibitors even after progression on chemotherapy. These observations have led to a clinical trial evaluating <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> inhibition in patients with <jats:styled-content style=\"fixed-case\">CCA<\/jats:styled-content> enriched for <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> alterations. This review summarizes current knowledge about the role of the <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content> pathway in cholangiocarcinogenesis and ongoing work in developing <jats:styled-content style=\"fixed-case\">FGFR<\/jats:styled-content>\u2010directed therapies as an antineoplastic strategy for <jats:styled-content style=\"fixed-case\">CCA<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/jgh.12916","type":"journal-article","created":{"date-parts":[[2015,2,13]],"date-time":"2015-02-13T13:22:09Z","timestamp":1423833729000},"page":"1116-1122","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Role of the fibroblast growth factor receptor axis in cholangiocarcinoma"],"prefix":"10.1111","volume":"30","author":[{"given":"Celina","family":"Ang","sequence":"first","affiliation":[{"name":"Division of Medicine, Hematology, and Medical Oncology Mount Sinai School of Medicine  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,6,10]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"American Cancer Society.Bile duct cancer (cholangiocarcinoma).2013American Cancer Society:Atlanta Georgia."},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.09.009"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.010561"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.126"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-2823"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.67"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.194"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1004135"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0386"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1477-2574.2010.00286.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098653"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.4787"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.706"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800204"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700236"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000251366.62632.d3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-007-9001-y"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11699"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5381"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-1-43"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/156800909789057006"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.007"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2005.00332.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0699"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.004"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.310"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038972"},{"key":"e_1_2_7_31_1","doi-asserted-by":"crossref","unstructured":"RiekeD ZuoZ ChawlaAet\u2009al.Effect of FGFR1 on epithelial\u2010mesenchymal transition and EGFR resistance in HNC: a systems biology approach.ASCO Meeting Abstracts2014;32:6091.","DOI":"10.1200\/jco.2014.32.15_suppl.6091"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-12-0275"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3843"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203186"},{"key":"e_1_2_7_35_1","first-page":"821","article-title":"Basic fibroblast growth factor induces cholangiocarcinoma cell migration via activation of the MEK1\/2 pathway","volume":"2","author":"Narong S","year":"2011","journal-title":"Oncol. Lett."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1386-6346(00)00117-0"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26890"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0352"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(14)60102-1"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2014.03.014"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2014.02.050"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0362"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0210"},{"key":"e_1_2_7_45_1","doi-asserted-by":"crossref","unstructured":"LangSA SchellerT MoserCet\u2009al.Targeting FGFR system in a model of HCC.AACR Annual Meeting Abstracts2012; Abstract 4373.","DOI":"10.1158\/1538-7445.AM2012-4373"},{"key":"e_1_2_7_46_1","doi-asserted-by":"crossref","unstructured":"NogovaL SequistLV CassierPAet\u2009al.Targeting FGFR1\u2010amplified lung squamous cell carcinoma with the selective pan\u2010FGFR inhibitor BGJ398.ASCO Meeting Abstracts2014;32:8034.","DOI":"10.1200\/jco.2014.32.15_suppl.8034"},{"key":"e_1_2_7_47_1","doi-asserted-by":"crossref","unstructured":"BahledaR DienstmannR AdamoBet\u2009al.Phase 1 study of JNJ\u201042756493 a pan\u2010fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors.ASCO Meeting Abstracts2014;32:2501.","DOI":"10.1200\/jco.2014.32.15_suppl.2501"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm051106d"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.4410"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3009"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.03.017"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2755"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0694"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-28"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0793"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1982-z"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25864"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.24148"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.028"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2129"},{"key":"e_1_2_7_63_1","doi-asserted-by":"crossref","first-page":"abstr 3057","DOI":"10.1200\/jco.2010.28.15_suppl.3057","article-title":"A phase I\/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: phase I results","volume":"28","author":"Angevin E","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0412"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2139-4"},{"key":"e_1_2_7_66_1","doi-asserted-by":"crossref","first-page":"abstr 2603","DOI":"10.1200\/jco.2014.32.15_suppl.2603","article-title":"A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors","volume":"32","author":"Fetterly GJ","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0450"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23131"},{"key":"e_1_2_7_70_1","doi-asserted-by":"crossref","unstructured":"OkitaK KumadaH IkedaKet\u2009al.Phase I\/II study of E7080 (lenvatinib) a multitargeted tyrosine kinase inhibitor in patients (pts) with advanced hepatocellular carcinoma (HCC): initial assessment of response rate.ASCO Meeting Abstracts2012;30:320.","DOI":"10.1200\/jco.2012.30.4_suppl.320"},{"key":"e_1_2_7_71_1","first-page":"4152","article-title":"SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors","volume":"60","author":"Laird AD","year":"2000","journal-title":"Cancer Res."},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-010-1320-2"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.011"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036713"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.2024"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1210093"}],"container-title":["Journal of Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.12916","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgh.12916","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgh.12916","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T13:55:51Z","timestamp":1696254951000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jgh.12916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,10]]},"references-count":75,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1111\/jgh.12916"],"URL":"https:\/\/doi.org\/10.1111\/jgh.12916","archive":["Portico"],"relation":{},"ISSN":["0815-9319","1440-1746"],"issn-type":[{"value":"0815-9319","type":"print"},{"value":"1440-1746","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,10]]},"assertion":[{"value":"2015-01-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}